Vanguard Group
PRVL

Vanguard Group’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Vanguard Group’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-835,120
Closed -$19.3M – 4371
2020
Q4 		$19.3M Buy
835,120
+69,274
+9% +$878K ﹤0.01% 2648
2020
Q3 		$7.8M Buy
765,846
+36,952
+5% +$496K ﹤0.01% 2914
2020
Q2 		$10.9M Buy
728,894
+364,402
+100% +$5.61M ﹤0.01% 2729
2020
Q1 		$4.44M Buy
364,492
+58,602
+19% +$932K ﹤0.01% 3017
2019
Q4 		$4.84M Buy
305,890
+71,431
+30% +$911K ﹤0.01% 3185
2019
Q3 		$2.88M Buy
234,459
+157,556
+205% +$1.79M ﹤0.01% 3324
2019
Q2 		$1.02M Buy
+76,903
New +$1.12M ﹤0.01% 3675

Vanguard Group's PRVL Position: Q1 2021 in Review

Vanguard Group sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 835,120 shares — an estimated $19.3M sold.

Vanguard Group first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $19.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Vanguard Group reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Vanguard Group sold 835,120 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $19.3M.
  • Vanguard Group first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
  • Vanguard Group's Prevail Therapeutics Inc. Common Stock position peaked at $19.3M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Vanguard Group's 13F filing for Q1 2021, filed 14 May 2021.